相关实验视频

Updated: Jun 13, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

威尼托克拉克斯与复发性或复发性急性髓性白血病的FLAG-IDA结合使用

Kai Wille¹, Marvin Dumke¹, Nadine Wilsdorf¹

¹University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany.

European journal of haematology

|September 10, 2024

概括

结合venetoclax和化疗的FLAVIDA疗法,在耐药性或复发性急性髓性白血病 (R/R-AML) 患者中改善了无事件生存期 (EFS). 这种组合疗法提供了一个有前途的替代方案,与标准治疗相比,反应率更高.

科学领域:

血液学血液学血液学
在瘤学瘤学.
临床治疗学临床治疗学

背景情况:

耐火性或复发性急性髓性白血病 (R/R-AML) 的预后通常是有限的.
结合化疗的Venetoclax (VEN) 正在成为改善R/R-AML.结果的战略.

研究的目的:

在R/R-AML患者中,比较标准救生化疗与venetoclax和FLAG-Ida (FLAVIDA) 组合的安全性和疗效.

主要方法:

一个回顾性,单中心研究,涉及53名R/R-AML患者.
标准救援化疗 (FLAG-Ida或HAM,n=35) 和FLAVIDA (n=18) 的比较.
平均随访时间为11.0个月.

主要成果:

与标准化疗相比,FLAVIDA显示出无事件生存时间 (EFS) 的统计显著增加 (HR 0.22 [95% CI 0.05, 0.97]).
没有观察到发烧性中性质或延迟血液恢复的显著差异.
弗拉维达 (FLAVIDA) 呈现出更高整体反应率 (78%对51%) 的趋势.

结论:

弗拉维达治疗方案是R/R-AML的有希望的治疗选择.
与标准化疗相比,FLAVIDA提供了较高的反应率和显著改善的EFS.

关键词:

弗拉维达是一位弗拉维达.急性髓细胞白血病 (AML) 白血病白血病耐火材料耐火材料耐火材料这是一个复发的复发.维尼托克拉克斯 (Venetoclax) 是一个

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...